




CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

CHM CDH17 Update
September 2025

20
25





DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words **“believes,” “plans,” “expects,” “anticipates,”** and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



INVESTMENT HIGHLIGHTS



4 Phase 1 clinical trials
under 3 FDA INDs at 4 leading US centres



Multiple clinical updates
in the next 12 months



Experienced leadership team
in cell therapy clinical development



CHM CDH17
the FIRST CDH17 CAR-T in clinical trials



First in class
CLTX-CAR for brain cancer



Robust and long life
patent portfolio

CORPORATE PROFILE

Stock code

ASX:CHM

Share price

\$0.003

52-week range

\$0.002-\$0.017

Market cap

~\$10m

Shares on issue

~3.2b

LEADERSHIP TEAM

EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION

4



Dr Rebecca McQUALTER
Chief Executive Officer



Dr Jason LITTEN
Chief Medical Officer



Dr Stephanie ASTROW
Chief Scientific Officer

EXPERIENCE

50+

Years of Cell Therapy
Experience

EXPERTISE

50+

Development
Programs

RESULTS

5/7

FDA-Approved
CAR T Cell Therapies





CHIMERIC THERAPEUTICS

CHM CDH17

Clinical Trial Update

September 2025

20
25



CDH17 OVERVIEW



Over a decade of development at the world-renowned cell therapy centre, The University of Pennsylvania



Compelling pre-clinical efficacy in gastric, pancreatic and neuroendocrine Cancers




Pre-clinical models indicate no toxicity in healthy cells



This is the first CDH17 CAR-T Cell Therapy in clinical trials in the world




CDH17 is protein on the surface of Gastrointestinal cancers (green on purple cell in picture)




Dr. Xianxin Hua,
M.D., Ph.D.




Dr. Carl June M.D.





ENCOURAGING PRE-CLINICAL RESULTS

CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models



Source: Feng et al., Nature Cancer, 2022



CHM CDH17 CAR-T PHASE 1 RECRUITING

The first CDH17 CAR T cell therapy in clinical trials globally

CHM CDH17 CAR-T

Technology from:



PHASE 1/2 TRIAL OPEN

4 sites actively recruiting

PERSONALISED CAR-T: AUTOLOGOUS

4 prestigious sites recruiting: [Sarah Cannon](#), [UPenn](#), [UChicago](#), [Emory](#)

FDA IND clearance: [Nov 23](#)


Manufacturing: [10/10 successful runs; GMP Compliant](#)

Phase 1/2 Trial Open in [Colorectal](#), [Gastric](#) and [Neuroendocrine Cancers](#)

10 patients enrolled: [8 patients treated](#), 2 awaiting dosing assignment

N= up to 15 patients

Phase 1/2 Clinical Trial of CHM CDH17 Design





CHM CDH17 PROGRESS AS AT 8 SEPTEMBER 2025

| Dose Level | Status | Notes |
|---------------|----------------------|--|
| 1 50m | Completed | 4 patients treated 1 patient remains on study |
| 2 150m | Recruitment ongoing | 4 patients treated |
| 3 450m | Recruitment underway | 2 patients awaiting dosing assignment |
| Manufacturing | GMP compliant | 10 out of 10 successful runs |

DOSE LEVEL 1 COMPLETED

| 50m Cells | Tumour Type | Status |
|-----------|-------------|---|
| Patient 1 | CRC | No follow up |
| Patient 2 | NET | Stable Disease until day 150 progression Grade 1 CRS |
| Patient 3 | CRC | Stable Disease at day 270 |
| Patient 4 | CRC | Progressive Disease at day 28 |



DOSE LEVEL 2 Ongoing

| 150m Cells | Tumour Type | Status |
|------------|-------------|---|
| Patient 5 | CRC | Stable Disease 90days Tumour Shrinkage 12% |
| Patient 6 | NET | Treated. Pending Day 28 scan Grade 3 CRS |
| Patient 7 | CRC | Treated. |
| Patient 8 | CRC | Treated. |

CRC= Colorectal Cancer (Bowel Cancer)

NET= NeuroEndocrine Tumour (Intestinal NET)





CHM CDH17 PROGRESS

13

CHIMERIC THERAPEUTICS

RECRUITMENT UNDERWAY

| TBD Dose of Cells | Tumour Type | Status |
|-------------------|-------------|---------------------------------------|
| Patient 9 | NET | Manufactured. Dose yet to be assigned |
| Patient 10 | NET | Manufactured. Dose yet to be assigned |
| TBD | | |
| TBD | | |



20
25

CRC= Colorectal Cancer (Bowel Cancer)

NET= NeuroEndocrine Tumour (Intestinal NET)



TOTAL GLOBAL MARKET SIZE





SUMMARY + FY26 CATALYSTS

CHM CDH17
CHM 2101

- 8 patients treated
- 10/10 manufacturing runs
- Anti-tumour activity observed
- No safety issues to date
- No off-target effects

FY26 Deliverables

- Complete Dose level 2
- Commence Dose level 3 (if appropriate)
- Conclude Phase 1
- Phase 2 readiness






CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

investors@chimerictherapeutics.com

20
25





CHM: BROAD PORTFOLIO

3 novel cell therapies; 4 clinical trials

CHM CDH17
CAR-T

Technology from:
 Penn
UNIVERSITY OF PENNSYLVANIA

PHASE 1/2 TRIAL OPEN
4 sites active

CHM CORE-NK
'OFF THE SHELF' NK

Technology from:
 CASE
WESTERN
RESERVE
UNIVERSITY

PHASE 1B TRIAL OPEN
MD Anderson

PHASE 1B TRIAL OPEN
Case Western

CHM CLTX

Technology from:
 City of
Hope®

Phase 1A completed: COH

PHASE 1B TRIAL
1 site active





CHM CDH17 CAR T

TARGET COMPETITORS IN DETAIL

| | Preclinical | Phase 1 | |
|------------------|--|--|--|
| Cell Therapy | <div style="background-color: #e1f5fe; padding: 10px; border-radius: 5px;"> CDH17 CAR T Ospedale San Raffaele </div> <div style="background-color: #ff7043; padding: 10px; border-radius: 5px;"> CHM CDH17 CDH17 CAR NK Chimeric Therapeutics </div> <div style="background-color: #1a237e; padding: 10px; border-radius: 5px;"> ARB011 CDH17 NK/T Arbele Bio </div> <div style="background-color: #e1f5fe; padding: 10px; border-radius: 5px;"> ARB001 CDH17 CAR T Arbele Bio </div> <div style="background-color: #e1f5fe; padding: 10px; border-radius: 5px;"> CDH17 CAR T +IL7/21 Eastern Theater General Hospital of PLA </div> | CHM CDH17 CDH17 CAR T Chimeric Therapeutics | |
| Non-Cell Therapy | <div style="background-color: #d9d9d9; padding: 10px; border-radius: 5px;"> CDH17 x pCAD ADC Novartis </div> <div style="background-color: #d9d9d9; padding: 10px; border-radius: 5px;"> AMT-676 CDH17 ADC Multitude Therapeutics </div> <div style="background-color: #d9d9d9; padding: 10px; border-radius: 5px;"> ARB101a CDH17 ADC Arbele Bio </div> <div style="background-color: #d9d9d9; padding: 10px; border-radius: 5px;"> CDH17 A4 CDH17 mAb Oxford Biotherapeutics </div> | <div style="background-color: #d9d9d9; padding: 10px; border-radius: 5px;"> TORL-3-600 CDH17 ADC TORL Biotherapeutics </div> <div style="background-color: #d9d9d9; padding: 10px; border-radius: 5px;"> BI 905711 CDH17xTRAILR2 bsAb Boehringer Ingelheim </div> <div style="background-color: #d9d9d9; padding: 10px; border-radius: 5px;"> Cabotamig (ARB202) CDH17 ADC Arbele Bio </div> | |

Legend

Chimeric
programsT cell
therapiesNK or NK/T
therapiesAustralian
biotech

Updated 03Jul24

